SHP465, a formulation of amphetamine salts, is being evaluated for safety and pharmacokinetics in a pediatric population (ages 4-5) with ADHD. The market for ADHD treatments is substantial, with increasing demand for effective therapies in younger populations. The completion of this Phase 1 trial positions Shire (now part of Takeda) to further explore the therapeutic potential of SHP465, particularly in a demographic that has limited treatment options. Competitive implications include the need to monitor existing ADHD medications and emerging therapies targeting similar patient populations. Diligence should focus on the safety profile and potential market entry strategies, given the stringent regulatory environment for pediatric medications.